Look back at pharma news in the week to October 18
By Barbara Obstoj-Cardwell. Editor
On the regulatory front last week there was good news for Eli Lilly with the US Food and Drug Administration approval of its migraine drug Reyvow (lasmiditan). Also, Reata Pharmaceuticals said it is preparing to file for regulatory for its Friedreich’s ataxia candidate omaveloxolone. Licensing activity featured Ipsen’s announcement of a deal with Blueprint Medicines for the latter’s BLU782 for the treatment of a rate severely disabling genetic disorder. M&A news featured Alexion Pharmaceuticals made a $930 million bid for Achillion and its targeting complement immune system.
Lilly’s 1-drug migraine business gets support with new approval
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze